News
Apogee Therapeutics recently reported positive 16-week results from its APEX Phase 2 Part A trial, with APG777 meeting all primary and key secondary endpoints in moderate-to-severe atopic dermatitis ...
Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...
The vitiligo treatment landscape is evolving with a shift towards targeted therapies, which have shown encouraging results in promoting repigmentatio ...
TipRanks on MSN13h
Pfizer’s Phase 3 Study on Abrocitinib: A Potential Game-Changer for Atopic Dermatitis Treatment
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 3 study titled ‘A Phase 3 Multi-Center, ...
TipRanks on MSN14h
Pfizer’s Latest Clinical Study on Abrocitinib for Pediatric Eczema: Key Insights for Investors
Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a clinical study titled A 16-WEEK, MULTICENTER, ...
Four out of 10 eczema patients struggle with sleep, and they may not volunteer that information unless you ask.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback